Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06802120
Recruiting Not applicable

Effects of Osteopathic Management on Disability and Quality of Life After Lumbar Arthrodesis

NCT06802120 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-01-02
Last updated
2026-01-06

Condition(s) studied

Chirurgical Intervention

Investigational drug(s) / intervention(s)

osteopathy realsham osteopathy

osteopathy real: treatment with real osteopathy 2 times a week for 8 weeks

sham osteopathy: treatment with sham osteopathy 2 times a week for 8 weeks

Study summary

The aim of our study is to assess the effect of a combined physiotherapy and osteopathy treatment versus a placebo on the management of disability and quality of life after lumbar arthrodesis. This study will provide a better assessment of the use of osteopathy as a non pharmacological approach to post-operative management.

For this purpose, We will analyze the effects of these two approaches, targeted and non-targeted osteopathy (TO vs. NTO), on patients' disability and quality of life after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * having experienced a lumbar arthrodesis (of one to three levels) four weeks before inclusion * being under a stable pharmacological treatment over the last month * who are suffering from postoperative mechanical pain (VAS ≥ 4) Exclusion Criteria: * neuropathic pain according to a DN4 score greater than or equal to 4/10, * are suffering from fibromyalgia, * algodystrophy, * other somatic or neuropsychiatric diseases (other than depression and anxiety), * have received osteopathic treatment over the last three month prior to inclusion, * are included in another interventional research protocol during the study period

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinique Bizet Paris France Recruiting

More Clinique Bizet trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06802120 on ClinicalTrials.gov ↗ ← All trials in France